Rna engineered t cells for the treatment of cancer
AssigneeThe Trustees of the University of Pennsylvania
InventorsCarl H. June, Yangbing Zhao
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for generating RNA Chimeric Antigen Receptor (CAR) transfected T cells. The RNA-engineered T cells can be used in adoptive therapy to treat cancer.
Claims62
An in vitro transcribed RNA or synthetic RNA comprising a nucleic acid sequence encoding an extracellular domain, a transmembrane domain, a costimulatory signaling region, and a signaling domain of CD3-zeta.
A T cell comprising an in vitro transcribed RNA or synthetic RNA, wherein the RNA comprises a nucleic acid sequence encoding an extracellular domain, a transmembrane domain, a costimulatory signaling region, and a signaling domain of CD3-zeta.
A method of generating a population of RNA-engineered T cells transiently expressing exogenous RNA, the method comprising introducing an in vitro transcribed RNA or synthetic RNA into a T cell, wherein the RNA comprises a nucleic acid sequence encoding an extracellular domain, a transmembrane domain, a costimulatory signaling region, and a signaling domain of CD3-zeta.
A method of treating a cancer patient, the method comprising administering to the patient a T cell engineered to transiently express exogenous RNA, wherein the RNA comprises a nucleic acid sequence encoding an extracellular domain, a transmembrane domain, a costimulatory signaling region, and a signaling domain of CD3-zeta.
Dependencies are inferred from the claim text.